Litigation Details for Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Docket	1:21-cv-01452	Date Filed	2021-10-14
Court	District Court, D. Delaware	Date Terminated	2023-05-30
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	11,058,667; 11,135,192; 9,517,226; 9,937,143
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-14				External link to document

Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. Litigation Analysis

Last updated: February 19, 2026

Litigation Overview

The United States District Court for the District of Delaware is presiding over patent litigation initiated by Novartis Pharmaceuticals Corporation against Crystal Pharmaceutical (Suzhou) Co., Ltd. The core dispute centers on alleged infringement of U.S. Patent No. 8,143,221, held by Novartis. Crystal Pharmaceutical’s product, known as Xiidra, is the subject of the infringement claim. Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease. Novartis alleges that Crystal Pharmaceutical's generic version of Xiidra, marketed as libvance, infringes upon claims 1, 2, 10, 11, 15, 16, and 23 of the '221 patent. Novartis seeks preliminary and permanent injunctions, as well as monetary damages, to prevent the market entry of libvance.

Patent at Issue

What is U.S. Patent No. 8,143,221?

U.S. Patent No. 8,143,221, titled "FORMULATIONS OF LFA-1 ANTAGONISTS FOR OPHTHALMIC USE," was issued to Novartis AG on March 27, 2012. The patent claims novel pharmaceutical formulations of lactimidopine, a leukocyte function-associated antigen 1 (LFA-1) antagonist, for ophthalmic administration. Lactimidopine is the active pharmaceutical ingredient in Xiidra. The patent's claims focus on specific formulations designed to improve the delivery, efficacy, and tolerability of LFA-1 antagonists for treating ocular surface diseases, particularly dry eye disease. The patent has an expiration date of March 26, 2030, with potential for patent term extension.

What specific claims of the '221 patent are at issue?

The litigation specifically targets claims 1, 2, 10, 11, 15, 16, and 23 of U.S. Patent No. 8,143,221. These claims broadly define pharmaceutical formulations containing an LFA-1 antagonist. For instance:

• Claim 1 describes a pharmaceutical formulation comprising an LFA-1 antagonist, a buffering agent, a tonicity agent, and a preservative.
• Claim 2 further specifies the LFA-1 antagonist as lactimidopine.
• Claims 10 and 11 detail specific pH ranges and concentrations for the buffering and tonicity agents.
• Claims 15 and 16 relate to the presence and type of preservative in the formulation.
• Claim 23 pertains to a method of treating dry eye disease using such a formulation.

These claims are central to Novartis's argument that Crystal Pharmaceutical's libvance product infringes its patented technology.

Allegations and Defense Strategies

What are Novartis's primary infringement allegations?

Novartis alleges that Crystal Pharmaceutical's libvance product directly infringes upon the asserted claims of the '221 patent. The gravamen of Novartis's complaint is that libvance embodies the pharmaceutical formulations claimed in the patent. Novartis contends that libvance contains lactimidopine as the active ingredient, along with other excipients that fall within the scope of the patent's claims, specifically regarding buffering agents, tonicity agents, and preservatives. Novartis further alleges that Crystal Pharmaceutical has engaged in induced and contributory infringement by marketing and selling libvance for use in treating dry eye disease, knowing that its use would infringe the '221 patent.

What are Crystal Pharmaceutical's likely defense arguments?

Crystal Pharmaceutical is expected to mount several defenses, commonly seen in Hatch-Waxman litigation. These include:

• Non-infringement: Crystal Pharmaceutical will likely argue that libvance does not practice the claimed invention. This could involve demonstrating that its formulation falls outside the specific parameters defined by the patent claims, such as specific pH ranges, concentrations of excipients, or types of preservatives. They may also argue that their formulation is structurally or functionally different from what is claimed.
• Invalidity: Crystal Pharmaceutical may challenge the validity of the '221 patent on grounds such as anticipation or obviousness. They could present prior art that predates the patent's filing date and demonstrates that the claimed invention was already known or would have been obvious to a person skilled in the art. Potential invalidity challenges could focus on the novelty and non-obviousness of the specific formulation aspects claimed.
• Lack of Enablement or Written Description: Crystal Pharmaceutical might argue that the '221 patent does not adequately describe or enable the full scope of its claims, potentially limiting their enforceability.

Procedural History and Key Filings

What is the current status of the litigation?

As of the most recent filings, the litigation is in its discovery phase. Both parties are exchanging information and evidence related to infringement, validity, and damages. Key court activities have included the initial pleadings, the filing of a complaint by Novartis, and an answer and counterclaims by Crystal Pharmaceutical. The court has also issued initial scheduling orders, setting deadlines for discovery and potential future claim construction hearings.

What are the significant filings in the case?

• Complaint (Filed June 30, 2021): Novartis initiated the lawsuit, alleging patent infringement and seeking injunctive and monetary relief.
• Answer and Counterclaims (Filed August 16, 2021): Crystal Pharmaceutical filed its response, denying infringement and asserting affirmative defenses, including challenges to patent validity.
• Motions for Preliminary Injunction: While not always filed in every patent case, Novartis may seek a preliminary injunction to prevent the market entry of libvance during the pendency of the litigation. Crystal Pharmaceutical would oppose such a motion.
• Claim Construction Briefs (Anticipated): As is standard in patent litigation, the parties will submit briefs arguing their interpretations of the patent's claims. The court will then hold a Markman hearing to determine the meaning of disputed claim terms, which is critical for assessing infringement.
• Discovery Requests: Extensive discovery is underway, including interrogatories, requests for production of documents, and depositions. This phase will generate substantial evidence regarding formulation details, manufacturing processes, and commercial intent.

Market and Commercial Implications

What is the market significance of Xiidra and libvance?

Xiidra is a significant product in the dry eye disease market. Launched by Shire, which was subsequently acquired by Takeda, and later licensed to Novartis, it is a first-in-class topical LFA-1 antagonist. The dry eye market is substantial and growing, driven by an aging population and increased awareness of the condition. The potential market entry of a generic version like libvance has considerable commercial implications:

• Price Competition: Generic entry typically leads to significant price reductions for the drug, impacting revenue for the brand-name product and shifting market share.
• Access and Affordability: Generic options can increase patient access to treatment due to lower costs.
• Novartis's Revenue: Novartis, as the current rights holder or licensor of Xiidra, stands to lose market share and revenue if generic libvance enters the market unimpeded.
• Crystal Pharmaceutical's Strategy: Crystal Pharmaceutical's objective is to capitalize on the market opportunity by offering a bioequivalent and lower-cost alternative to Xiidra.

How do patent expiration dates and potential extensions impact the litigation?

The '221 patent has an expiration date of March 26, 2030. However, this expiration date can be subject to Patent Term Extension (PTE) under the Hatch-Waxman Act, which aims to compensate for patent term lost during regulatory review. If the '221 patent is eligible for and receives PTE, its effective expiration date could be extended. The determination of PTE eligibility and duration is a separate regulatory process but can significantly influence the commercial viability of a generic product. For Crystal Pharmaceutical, the effective patent life post-approval of libvance is a critical factor in their investment and market entry strategy. The outcome of this litigation will dictate whether libvance can launch before the '221 patent expires or becomes potentially extended, and under what conditions.

Key Takeaways

• Novartis Pharmaceuticals Corporation is litigating U.S. Patent No. 8,143,221 against Crystal Pharmaceutical (Suzhou) Co., Ltd. over alleged infringement by Crystal Pharmaceutical's generic dry eye drug, libvance.
• The '221 patent claims specific ophthalmic formulations of lactimidopine, the active ingredient in Xiidra.
• Novartis alleges direct, induced, and contributory infringement, seeking to block libvance's market entry.
• Crystal Pharmaceutical is likely to defend by asserting non-infringement and challenging the patent's validity.
• The litigation is in the discovery phase, with claim construction and potential Markman hearings anticipated.
• The market for dry eye treatments is substantial, and the entry of a generic competitor like libvance carries significant commercial implications for pricing, market share, and revenue.
• The effective expiration date of the '221 patent, including any potential Patent Term Extension, is a critical factor in the long-term commercial outlook for both parties.

Frequently Asked Questions

1. What is the primary legal basis for Novartis's lawsuit against Crystal Pharmaceutical?

Novartis's lawsuit is based on allegations of patent infringement. Specifically, Novartis claims that Crystal Pharmaceutical's generic product, libvance, infringes upon one or more claims of U.S. Patent No. 8,143,221, which covers formulations of lactimidopine for ophthalmic use.

2. Can Crystal Pharmaceutical launch libvance before the litigation is resolved?

Crystal Pharmaceutical may be able to launch libvance if they have received FDA approval for their Abbreviated New Drug Application (ANDA) and if they are not subject to an injunction. However, if Novartis prevails in its claim for a preliminary or permanent injunction, Crystal Pharmaceutical's launch could be delayed or blocked. The timing of an FDA approval relative to court rulings is a critical determinant.

3. What does "claim construction" mean in the context of this patent litigation?

Claim construction, often referred to as a Markman hearing, is a process in patent litigation where the court interprets the meaning and scope of disputed terms within the patent claims. This interpretation is crucial because it establishes what the patent actually protects, which is fundamental to determining whether a product infringes the patent.

4. What are the potential outcomes of this litigation for Novartis?

If Novartis prevails, the court could issue injunctions preventing Crystal Pharmaceutical from launching or selling libvance, and Novartis could be awarded monetary damages for past infringement. If Crystal Pharmaceutical prevails, libvance could enter the market, potentially without restriction, and Novartis may face challenges to the validity of its patent.

5. How does the Hatch-Waxman Act influence this type of patent litigation?

The Hatch-Waxman Act governs the abbreviated approval process for generic drugs in the U.S. It provides a framework for resolving patent disputes between brand-name and generic drug manufacturers. Key provisions include the Paragraph IV certification, where a generic company certifies that its product does not infringe a listed patent or that the patent is invalid, invalid, or will expire. This act often triggers patent litigation and influences the strategic decisions of both parties regarding market entry and patent challenges.

Citations

[1] Complaint for Patent Infringement, Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd., No. 1:21-cv-01452 (D. Del. June 30, 2021). [2] Answer and Counterclaims, Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd., No. 1:21-cv-01452 (D. Del. Aug. 16, 2021). [3] U.S. Patent No. 8,143,221 (filed Oct. 1, 2010) issued Mar. 27, 2012. [4] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDA Submissions—Refuse-to-Receive Standards. Retrieved from [FDA website relevant to ANDA process].